Daxor Awarded Defense Contract to Develop Rapid Portable Blood Volume Analyzer

Daxor Corporation announced that the U.S. Department of Defense (DOD) has awarded the company a contract for the development and deployment of a small, portable, highly accurate, battery-powered blood volume analyzer.
 
“The value of blood volume measurement for improving outcomes is further validated by this important contract from the U.S. military for our technology,” commented Daxor Corporation CEO Michael Feldschuh. “Whether helping to treat COVID-19 patients in the hospital setting as we are doing now, or helping with trauma and burn patients in the military or civilian setting, Daxor’s current and future systems are a leap forward from the current standard of care for volume assessment and provide better patient results in numerous settings.”
 
In order to improve combat casualties, Daxor, alongside the DOD, developed a small, portable, highly accurate, battery-powered prototype of its flagship product, the BVA-100. To ensure optimal delivery, Daxor has ramped up its research and production capabilities to prioritize this contract and plans to generate significant production capabilities in the next 18 months. The company believes this contract further validates the value of its blood volume technology, as this prototype, which has been under development for the past two years, promises to improve casualty care in saving many more lives within the armed forces.
 
“We are developing innovative instrumentation that is faster and simpler to use, capable of giving complete volume status in as little as 12 minutes,” said Jonathan Feldschuh, chief science officer of Daxor. “Building on Daxor’s core technology, the new device will enable caretakers and clinicians to make precise and timely decisions for medication administration and determining patient-specific treatment.”
 
Once the company moves into mass-manufacturing the advanced device, both parties agree that this new technology is also suitable for civilian use in hospitals and outpatient settings. Moreover, with its framework tied to hospitals and ICUs, Daxor will have the ability to bring this new technology to the broader healthcare market.
 
“This is an important step forward for Daxor as the DOD has indicated that Daxor’s next-generation blood volume technology may provide an important addition to military medicine, recognizing its essential need within civilian medical applications,” added Soren Thompson, the company’s vice president of Development.
 
Daxor was first selected by the U.S. government’s Small Business Innovative Research (SBIR) department in 2018. Following close collaboration and continued development between Daxor and the Department of Defense, Daxor began execution of the contract as specified in the agreement on May 1. Daxor has filed multiple new patents with the U.S. Patent and Trademark Office related to the development of the technology and support of its features.
 
Daxor’s BVA-100 has been used in over 45,000 patient clinical assessments as well as featured in over 100 published research studies, trials, poster presentations, and case studies from leading institutions such as the Mayo Clinic, Cleveland Clinic, the VA, Yale University School of Medicine, Christiana Care Health System of Newark, Vanderbilt University Medical Center, Virginia Commonwealth University, and Queen’s Medical Center, among others.